Blue Cross Blue Shield · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as not FDA-approved for this use by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Diagnosis confirmed by lab tests (e.g., A1C ≥6.5%).

Source policy: Blue Cross Blue Shield tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Blue Cross Blue Shield angle on Tirzepatide

## BCBS "Not FDA-Approved" Denials on Tirzepatide: Decoding the Indication Mismatch

A "not FDA-approved" denial on tirzepatide from a Blue Cross Blue Shield plan is almost never a literal statement — tirzepatide is FDA-approved as Mounjaro (T2DM, May 2022) and Zepbound (chronic weight management, November 2023). What the BCBS adjudicator is actually saying is indication mismatch: the submitted diagnosis code does not match the FDA-labeled indication for the NDC dispensed, or the prescriber attempted a Zepbound fill against a T2DM benefit (or vice versa). Anthem BCBS plans route this through Carelon Medical Benefits Management for prior authorization on the medical side and CarelonRx/IngenioRx on the pharmacy side; Horizon BCBSNJ uses Prime Therapeutics; BCBS Texas/Illinois/Montana/Oklahoma/New Mexico (HCSC) route behavioral and specialty review through Prime and Magellan respectively; BCBSMA uses Express Scripts. The exact CPB you must cite back at them depends on the licensee — for example, Anthem Clinical UM Guideline CG-DRUG-141 (Tirzepatide) and BCBSNC Corporate Medical Policy "Glucagon-Like Peptide-1 Receptor Agonists" both require A1C ≥6.5% or fasting glucose ≥126 mg/dL documentation for the Mounjaro indication.

The procedural lever is precise. Pull the denial EOB and the underlying clinical criteria document (ERISA plans must produce this under 29 CFR §2560.503-1(g)(1)(v)(B) within 30 days of request — failure tolls the appeal clock and is independently actionable). Match your submitted ICD-10 to the policy's covered indication table: E11.x codes for Mounjaro, E66.01 with BMI ≥30 (or ≥27 with comorbidity) for Zepbound. If the diagnosis is correct, the denial is procedurally defective — the plan conflated "off-label" with "not FDA-approved" and you cite the package insert directly.

If the use is genuinely off-label (e.g., Mounjaro for weight loss without T2DM), the Pinto v. Aetna (10th Cir. 2014) framework still helps: the plan bears the burden of showing the exclusion clearly applies, and compendial support in DrugDex Level 1/2a or AHFS triggers most BCBS "medically accepted indication" clauses. For ACA-regulated individual/small group plans, 45 CFR §156.122(a)(3) prohibits exclusion of an FDA-approved drug solely because it is not on formulary when medically necessary — useful when the real issue is formulary substitution being mislabeled as an FDA approval issue.

Tactical tip: Before filing the level-1 appeal, call the BCBS pharmacy help desk and ask the rep to read the denial reason code verbatim (e.g., Anthem code 569 vs. 75). "Not FDA-approved" in the member letter often maps to a granular internal code like "diagnosis not on covered indication list" — quoting that code in your appeal header forces the reviewer to address the actual rule rather than the consumer-facing summary. If the licensee is fully-insured, file a parallel complaint with your state DOI; HCSC and Anthem state-by-state response times accelerate sharply once a DOI file number is attached.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other insurers on Tirzepatide

Other denial reasons for Blue Cross Blue Shield Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.